Epigenetic biomarkers in prostate cancer: Current and future uses.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Letters

• Publication date

  2014-01-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.canlet.2012.02.011PMID 22391123
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry.

  2013cited by this paper
• Global Histone H3K27 Methylation Levels are Different in Localized and Metastatic Prostate Cancer

  2012cited by this paper
• DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate Cancer

  2012cited by this paper
• Changes in circulating microRNA levels associated with prostate cancer

  2012cited by this paper
• Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease

  2012cited by this paper
• Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer

  2012cited by this paper
• Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma

  2012cited by this paper
• MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening

  2012cited by this paper
• Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high‐risk cohort of men with negative initial prostate biopsies

  2012cited by this paper
• Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.

  2011cited by this paper
• A study of methylated glutathione s-transferase 1 (mGSTP1)as a potential plasma epigenetic marker of response to chemotherapy and prognosis in men with castration-resistant prostate cancer (CRPC).

  2011cited by this paper
• Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay.

  2011cited by this paper
• Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers

  2011cited by this paper
• Circulating miRNAs are correlated with tumor progression in prostate cancer

  2011influential reference
• Tumour markers in prostate cancer III: Biomarkers in urine

  2011cited by this paper
• Cell-free nucleic acids as biomarkers in cancer patients

  2011cited by this paper
• Platinum Priority – Collaborative Review – Prostate Cancer MicroRNA in Prostate , Bladder , and Kidney Cancer : A Systematic Review

  2011cited by this paper
• GSTP1 DNA Methylation and Expression Status Is Indicative of 5-aza-2′-Deoxycytidine Efficacy in Human Prostate Cancer Cells

  2011cited by this paper
• Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression

  2011cited by this paper
• Improvement of Prostate Cancer Detection by Integrating the PSA Test With miRNA Expression Profiling

  2011cited by this paper
• Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers

  2011cited by this paper
• Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine

  2011cited by this paper
• Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer

  2011cited by this paper
• Increased methylation variation in epigenetic domains across cancer types

  2011cited by this paper
• Tumor markers in prostate cancer I: Blood-based markers

  2011cited by this paper
• MicroRNAs and epigenetics

  2011cited by this paper
• Epigenetics in prostate cancer: biologic and clinical relevance.

  2011cited by this paper
• Global levels of histone modifications predict prostate cancer recurrence

  2010cited by this paper
• Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.

  2010cited by this paper
• Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials

  2010cited by this paper
• Diet, MicroRNAs and Prostate Cancer

  2010cited by this paper
• Promoter hypermethylation in prostate cancer.

  2010cited by this paper
• Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy.

  2010cited by this paper
• Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

  2010cited by this paper
• MicroRNAs and prostate cancer.

  2010cited by this paper
• Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer

  2010cited by this paper
• MicroRNAs and prostate cancer.

  2010cited by this paper
• miR‐34c is downregulated in prostate cancer and exerts tumor suppressive functions

  2010cited by this paper
• Methylated genes as potential biomarkers in prostate cancer

  2010cited by this paper
• How epigenetics can explain human metastasis: A new role for microRNAs

  2009cited by this paper
• Mortality results from a randomized prostate-cancer screening trial.

  2009cited by this paper
• MicroRNA profile analysis of human prostate cancers

  2009cited by this paper
• Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma

  2009cited by this paper
• The value of EZH2, p27kip1, BMI‐1 and MIB‐1 on biopsy specimens with low‐risk prostate cancer in selecting men with significant prostate cancer at prostatectomy

  2009cited by this paper
• Global levels of histone modifications predict prognosis in different cancers.

  2009cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009cited by this paper
• Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.

  2009cited by this paper
• Multicenter evaluation of an investigational prostate cancer methylation assay.

  2009cited by this paper
• MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

  2009cited by this paper
• Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate cancer.

  2009cited by this paper
• MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer

  2009cited by this paper
• Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1

  2009cited by this paper
• How epigenetics can explain human metastasis: a new role for microRNAs.

  2009cited by this paper
• Convergence of Mutation and Epigenetic Alterations Identifies Common Genes in Cancer That Predict for Poor Prognosis

  2008cited by this paper
• Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non–Small Cell Lung Cancer

  2008cited by this paper
• DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.

  2008cited by this paper
• Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores

  2008cited by this paper
• Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers

  2008cited by this paper
• Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer.

  2008cited by this paper
• The Global Histone Modification Pattern Correlates with Cancer Recurrence and Overall Survival in Gastric Adenocarcinoma

  2008cited by this paper
• Promoter hypermethylation in circulating blood cells identifies prostate cancer progression

  2008cited by this paper
• miRNAs: effectors of environmental influences on gene expression and disease.

  2008cited by this paper
• Development of a multiplexed urine assay for prostate cancer diagnosis.

  2008cited by this paper
• Circulating microRNAs as stable blood-based markers for cancer detection

  2008cited by this paper
• Sequence-specific histone methylation is detectable on circulating nucleosomes in plasma.

  2008cited by this paper
• CpG Island hypermethylation in cell‐free serum DNA identifies patients with localized prostate cancer

  2008cited by this paper
• Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators

  2008cited by this paper
• EZH2, Ki‐67 and MCM7 are prognostic markers in prostatectomy treated patients

  2008cited by this paper
• A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.

  2007cited by this paper
• Global histone modifications predict prognosis of resected non small-cell lung cancer.

  2007cited by this paper
• DNA methylation of GSTP1 as biomarker in diagnosis of prostate cancer.

  2007cited by this paper
• Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage

  2007cited by this paper
• High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients

  2007cited by this paper
• The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.

  2007cited by this paper
• Methylation of Human MicroRNA Genes in Normal and Neoplastic Cells

  2007cited by this paper
• Hypermethylation of CpG island loci and hypomethylation of LINE‐1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features

  2007cited by this paper
• Chromatin modifications and their function.

  2007cited by this paper
• Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007.

  2007cited by this paper
• Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.

  2007cited by this paper
• Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer

  2007cited by this paper
• MicroRNA expression profiling in prostate cancer.

  2007cited by this paper
• Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.

  2007cited by this paper
• Epigenetic regulation of nuclear steroid receptors.

  2006cited by this paper
• EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

  2006cited by this paper
• Epigenetics of prostate cancer: beyond DNA methylation

  2006cited by this paper
• Epigenetic therapy of cancer: past, present and future

  2006cited by this paper
• The emerging roles of DNA methylation in the clinical management of prostate cancer.

  2006cited by this paper
• Dynamic nucleosomes and gene transcription.

  2006cited by this paper
• The application of epigenetic modifiers on the treatment of prostate and bladder cancer.

  2006cited by this paper
• CD44 and PTGS2 Methylation are Independent Prognostic Markers for Biochemical Recurrence Among Prostate Cancer Patients with Clinically Localized Disease

  2006cited by this paper
• Epigenetics, disease, and therapeutic interventions.

  2006cited by this paper
• Histone modifications: signalling receptors and potential elements of a heritable epigenetic code.

  2006cited by this paper
• De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2′-deoxycytidine

  2005cited by this paper
• Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci

  2005cited by this paper
• Multigene Methylation Analysis for Detection and Staging of Prostate Cancer

  2005cited by this paper
• Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy

  2005cited by this paper
• Methylation of DNA — One of the Major Epigenetic Markers

  2005cited by this paper
• Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.

  2005cited by this paper

• Epigenetic alterations in prostate cancer: the role of chromatin remodeling.

  2025cites this paper
• Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders

  2025cites this paper
• Epigenetic regulation of androgen dependent and independent prostate cancer.

  2024cites this paper
• Combination of DNA methylation biomarkers with multiparametric magnetic resonance and ultrasound imaging fusion biopsy to detect the local spread of prostate cancer

  2023cites this paper
• Lineage Plasticity and Stemness Phenotypes in Prostate Cancer: Harnessing the Power of Integrated “Omics” Approaches to Explore Measurable Metrics

  2023cites this paper
• Circulating microRNA expression profiles to identify a potential link between prostate cancer and obesity

  2022cites this paper
• A Study to Investigate the Role of Noncoding RNA miR146 Alpha as a Potential Biomarker in Prostate Cancer

  2022cites this paper
• Consistent DNA Hypomethylations in Prostate Cancer

  2022cites this paper
• Tumour markers in prostate cancer: The post-prostate-specific antigen era

  2021cites this paper
• CMAR_A_336671 9095..9106

  2021cites this paper
• miR-145-5p: A Potential Biomarker in Predicting Gleason Upgrading of Prostate Biopsy Samples Scored 3+3=6

  2021cites this paper
• Discovery of Small Molecule Inhibitors for Histone Methyltransferases in Cancer

  2020cites this paper
• A Three-Gene Classifier Associated With MicroRNA-Mediated Regulation Predicts Prostate Cancer Recurrence After Radical Prostatectomy

  2020cites this paper
• A health disparities study of MicroRNA-146a expression in prostate cancer samples derived from African American and European American patients.

  2020cites this paper
• Computational Detection of Breast Cancer Invasiveness with DNA Methylation Biomarkers

  2020cites this paper
• Advances in Prognostic Methylation Biomarkers for Prostate Cancer

  2020cites this paper
• 5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors

  2019cites this paper
• Application of intercalating molecules in detection of methylated DNA in the presence of silver ions

  2019cites this paper
• UNC5D, suppressed by promoter hypermethylation, inhibits cell metastasis by activating death‐associated protein kinase 1 in prostate cancer

  2019cites this paper
• Biomarker discovery for disease progression and metastasis in prostate cancer : a multi-omic approach

  2019cites this paper
• Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data

  2019cites this paper
• Identification of hub genes in prostate cancer using robust rank aggregation and weighted gene co-expression network analysis

  2019cites this paper
• Pharmacoepigenetics of Chinese Herbal Components in Cancer

  2019cites this paper
• Paederia foetida induces anticancer activity by modulating chromatin modification enzymes and altering pro-inflammatory cytokine gene expression in human prostate cancer cells.

  2019cites this paper
• Novel multifunctional nanocarrier-mediated codelivery for targeting and treatment of prostate cancer

  2019cites this paper
• Isothiocyanates, Epigenetics, and Cancer Prevention

  2019cites this paper
• MESTRADO INTEGRADO EM MEDICINA INSTITUTO DE CIÊNCIAS BIOMÉDICAS ABEL SALAZAR AUTHOR

  2018cites this paper
• Methylation and MicroRNA Profiling to Understand Racial Disparities of Prostate Cancer.

  2018cites this paper
• Discrimination of methylated and nonmethylated region of a colorectal cancer related promoter using fluorescence enhancement of gold nanocluster at intrastrand of a 9C-loop

  2018cites this paper
• Potential Epigenetic Biomarkers for Prostate Cancer Screening

  2018influential citation
• Molecular Mechanisms of Advanced Prostate Cancer

  2018cites this paper
• Electrochemical affinity biosensors for fast detection of gene-specific methylations with no need for bisulfite and amplification treatments

  2018cites this paper
• In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer

  2018cites this paper
• Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients

  2018cites this paper
• The Emerging Role of Epitranscriptomics in Cancer: Focus on Urological Tumors

  2018cites this paper
• Fluorescence enhancement of silver nanocluster at intrastrand of a 12C-loop in presence of methylated region of sept 9 promoter.

  2018cites this paper
• Electrochemical Sensing of Cancer‐related Global and Locus‐specific DNA Methylation Events

  2018cites this paper
• Enhanced Anti-Cancer Capability of Ellagic Acid Using Solid Lipid Nanoparticles (SLNs)

  2018cites this paper
• RHCG and TCAF 1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy

  2017cites this paper
• MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors

  2017cites this paper
• miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men.

  2017cites this paper
• Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study

  2017cites this paper
• Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives

  2017cites this paper
• P110β Inhibition Reduces Histone H3K4 Di‐Methylation in Prostate Cancer

  2017cites this paper
• Promoter CpG‐Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer

  2017cites this paper
• Identifying aggressive prostate cancer foci using a DNA methylation classifier

  2017cites this paper
• Gene-set Analysis with CGI Information for Differential DNA Methylation Profiling

  2016cites this paper
• MiR-675 is over-expressed in patients with prostate cancer

  2016cites this paper
• A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma

  2016cites this paper
• An introduction to genetic and epigenetic changes in prostate gland – implications in efficacy of phytotherapy of benign prostatic hyperplasia and prostate cancer

  2016cites this paper
• DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects

  2016cites this paper
• Epigenetic Biomarkers of Disease

  2016cites this paper
• A 2015 survey of established or potential epigenetic biomarkers for the accurate detection of human cancers

  2016cites this paper
• Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer

  2016cites this paper
• RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy

  2016cites this paper
• Multigene Methylation Analysis And The Noninvasive Diagnosis Of Prostate Cancer From Body Fluids

  2016cites this paper
• Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer

  2016cites this paper
• Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis

  2015cites this paper
• Maternal Energetics and the Developmental Origins of Prostate Cancer in Offspring

  2015cites this paper
• Caracterización molecular y citogenética de pacientes con cáncer

  2015cites this paper
• Genomics and Epigenomics of Prostate Cancer

  2015cites this paper
• Epigenetic repression of regulator of G‐protein signaling 2 by ubiquitin‐like with PHD and ring‐finger domain 1 promotes bladder cancer progression

  2015cites this paper
• Клиническая значимость генетической характеризации рака предстательной железы: обзор литературы

  2015cites this paper
• Epigenetic potential of resveratrol and analogs in preclinical models of prostate cancer

  2015cites this paper
• Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer

  2015cites this paper
• High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer

  2015cites this paper
• Dissecting the prostate cancer stem cell niche inside the bone marrow

  2015cites this paper
• Clinical relevance of prostate cancer genetic characterization: literature review

  2015cites this paper
• Clinically relevant genetic characterization of prostate tumors: How close are we to the goal?

  2015influential citation
• Pterostilbene, a Potent Analog of Resveratrol, a Therapeutic Agent in Prostate Cancer: Epigenetic Mechanisms of Action

  2015cites this paper
• Targeting the genes of 9p13.3 amplicon in prostate cancer

  2015influential citation
• Diagnostic and Prognostic Utility of a DNA Hypermethylated Gene Signature in Prostate Cancer

  2014cites this paper
• The Role of MIR-34a in Inhibition of Prostate Tumor Growth in the bone and Induction of Autophagy

  2014cites this paper
• Micrornas in solid tumors

  2014cites this paper
• Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up

  2014cites this paper
• Aberrant Methylation of PCDH10 Predicts Worse Biochemical Recurrence-Free Survival in Patients with Prostate Cancer After Radical Prostatectomy

  2014cites this paper
• Prognostic DNA Methylation Markers for Prostate Cancer

  2014cites this paper
• Promoter Methylation of Protocadherin8 is an Independent Prognostic Factor for Biochemical Recurrence of Early-Stage Prostate Cancer

  2014cites this paper
• Validation Study of Genes with Hypermethylated Promoter Regions Associated with Prostate Cancer Recurrence

  2014influential citation
• Aberrant Methylation of Protocadherin 17 and its Clinical Significance in Patients with Prostate Cancer after Radical Prostatectomy

  2014cites this paper
• Natural products and transforming growth factor-beta (TGF-β) signaling in cancer development and progression.

  2013cites this paper
• Common gene pathways and families altered by DNA methylation in breast and prostate cancers.

  2013cites this paper
• Impact of Glutathione-S-Transferases (GST) Polymorphisms and Hypermethylation of Relevant Genes on Risk of Prostate Cancer Biochemical Recurrence: A Meta-Analysis

  2013cites this paper
• Detection of histone modification by chromatin immunoprecipitation combined zinc finger luciferase-based bioluminescence resonance energy transfer assay.

  2013cites this paper
• Prostate Cancer : Molecular Mechanisms and Therapeutics

  2013cites this paper
• The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer

  2013cites this paper
• Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.

  2012cites this paper
• TGF-β mediated DNA methylation in prostate cancer

  2012cites this paper